Back to Flash News

Dragonfly COO: Smaller startups should put $5 million into products and sales rather than Washington policy

Will Phillips posted on X that he asked Dragonfly Chief Operating Officer Lindsay Lin why smaller startups do not build strategic relationships with Washington. Lin responded that after securing $5 million in funding, the money should be prioritized for products and sales; unless policy itself is at the core of the business, using resources on policy relationships is a misallocation. The comment was taken from the full INSIDE episode featuring Phillips and Dragonfly.

Dragonfly is a crypto venture capital firm that manages about $4 billion and recently closed its fourth fund at $650 million. Its partners include Haseeb Qureshi and others, and Lindsay Lin serves as partner and chief operating officer. She previously worked at the Stellar Development Foundation and holds a J.D. from Harvard Law School. In the episode, Phillips visited Dragonfly portfolio companies including Monad, Rain Cards and Polymarket, discussing how they turn views on financial trends into investment decisions.

The view clearly distinguishes early capital allocation between prioritizing product and sales and investing in policy. For businesses that are not centered on policy, if $5 million in funding is diverted to Washington relationships, it will crowd out the resources needed for product iteration and sales validation. Dragonfly itself, as an institution managing tens of billions of dollars, participates in the submission of regulatory comment letters on matters such as CFTC prediction markets and compute derivatives, showing that it has the ability to invest in policy after scaling up; but for early-stage startups, that path is defined as a suboptimal allocation. The direct path from capital raising to product and sales stands in contrast to the long-term investment required for policy relationships.

Source: x.com/willsclips_/status/2121728723254911186

ABAB AI Insight

Historical structure: Venture capital’s allocation to early-stage startups has long emphasized prioritizing product and market validation, while policy and regulatory investment usually appears only after scale increases or the business is directly affected by regulation. Similar cases show that when funding is in the range of several million dollars, diverting resources to government relations prolongs the product validation cycle and reduces the probability of early survival.

Capital path: The $5 million funding is explicitly directed toward product development and sales rather than Washington strategic relationships. As an institution managing about $4 billion, Dragonfly submits comment letters on regulatory matters such as the CFTC, reflecting policy investment after scaling up; for small startups, that path is defined as a resource misallocation, with capital prioritizing links that can directly generate users and revenue.

Comparison: Unlike businesses whose core is policy or regulation, such as compliance services or heavily regulated financial products, early-stage general tech or crypto startups view policy investment as unnecessary. Compared with larger institutions later on, early companies lack the capital and workforce density to cover both product and policy, so they choose to focus on product and sales.

Judgment: Pricing power is shifting from policy relationships and regulatory access toward product validation and sales efficiency. If a business does not depend on policy as its core, the optimal allocation of early capital is product and sales; if policy becomes a prerequisite for survival, that priority will reverse. The structural change is that the scale of early financing determines whether policy investment constitutes a misallocation, rather than being a universally viable strategy.

ABAB News · Cognitive Law
$5 million prioritized for product sales rather than policy relationships
Policy investment appears only when the business is core or after scale increases
Misallocated early capital lengthens the validation cycle and lowers survival rates